首页> 中文期刊> 《中国当代医药》 >米非司酮联合米索前列醇治疗子宫内膜不典型增生的临床效果观察

米非司酮联合米索前列醇治疗子宫内膜不典型增生的临床效果观察

         

摘要

Objective To invstigate the effect of mifepristone combined with misoprostol in treatment of atypical en-dometrial hyperplasia. Methods 54 patients with atypical endometrial hyperplasia treated in our hospital from May 2012 to May 2014 were randomly divided into control group and observation group,27 patients in each group,only mifepristone was given to the control group,misoprostol was added to the observation group on the basis of control group treatment,the course of treatment were 72 days.The drug adverse reactions were recorded during the treatment,endome-trial was examined after treatment,then the effects of the two groups were analyzed. Results The total effective rate of the observing group was 92.59%,higher than 70.37%of the control group,the difference was significant (P<0.05).After treat-ment,the endometrial of the observation group was lower than that of the control group,the difference was significant (P<0.05).The incidence of adverse reactions between the two groups had no significant difference (P>0.05). Conclusion Mifepri-stone combined with misoprostol in treatment of atypical endometrial hyperplasia has significant effect,and the security is high,has good application value.%目的:探讨米非司酮联合米索前列醇治疗子宫内膜不典型增生的临床效果和安全性。方法将2012年5月~2014年5月在本院治疗的54例子宫内膜不典型增生患者随机分为对照组与观察组各27例,对照组给予米非司酮进行治疗,观察组在对照组治疗的基础上给予米索前列醇进行治疗,1个疗程为72 d。治疗过程中详细记录患者的用药不良反应,疗程结束后检查患者的子宫内膜,评价两组的临床效果。结果观察组总有效率为92.59%,高于对照组的70.37%,差异有统计学意义(P<0.05)。治疗后,观察组子宫内膜厚度低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率差异无统计学意义(P>0.05)。结论米非司酮联合米索前列醇治疗子宫内膜不典型增生效果显著,安全性高,有较好的应用价值。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号